Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Longitudinal Analysis of Tear Cytokine Ratios in Association with Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study
Author Affiliations & Notes
  • Cindy Siyang Zhao
    Ophthalmology, Stanford Health Care, Stanford, California, United States
  • Yineng Chen
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Gui-Shuang Ying
    Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Penny A Asbell
    Biomedical Engineering, The University of Memphis, Memphis, Tennessee, United States
  • Footnotes
    Commercial Relationships   Cindy Zhao None; Yineng Chen None; Gui-Shuang Ying None; Penny Asbell None
  • Footnotes
    Support  National Eye Institute Grants U10EY022879, U10EY022881, R21EY031338, and R01EY026972
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 415. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Cindy Siyang Zhao, Yineng Chen, Gui-Shuang Ying, Penny A Asbell; Longitudinal Analysis of Tear Cytokine Ratios in Association with Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study. Invest. Ophthalmol. Vis. Sci. 2024;65(7):415.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Interest in tear cytokines is driven by hope for a biomarker which aligns pathophysiology with the signs and symptoms of dry eye disease (DED). Prior work showed cross-sectional association between cytokine ratios (CRs) of pro- to anti-inflammatory cytokines with some DED signs. This secondary analysis describes longitudinal change in these CRs and associations with changes in DED signs and symptoms.

Methods : Secondary analysis of fifty-four subjects [mean age 57.3 (SD 13.2), 46/54 (85.2%) female; 37/54 (68.5%) white] whom had sufficient tear volumes (≥ 4 uL pooled from two eyes) at months 0, 6, and 12 for cytokine measurement. Pro-inflammatory (IL-1b, IL-6, IL-8, IL-17A, IFN-g, and TNF-a) to anti-inflammatory (IL-6, IL-10) cytokine ratios (CR) were calculated. DED signs (corneal and conjunctival staining scores, tear break-up time, Schirmer test, Meibomian gland plugging, tear osmolarity, composite sign severity score) and symptoms [Ocular Surface Disease Index (OSDI)] were also measured. Spearman correlation coefficients (rho) between changes in CR and changes in DED signs and symptoms over time were calculated.

Results : DED signs that improved over time (p <0.001) included conjunctival staining score [2.8 (SD 1.3) at month 0, 1.9 (SD 1.4) at month 6, 1.9 (SD 1.3) at month 12], corneal staining score [4.4 (SD 2.3) at month 0, 3.7 (SD 2.1) at month 6, 3.8 (SD 2.4) at month 12], and tear break-up time [2.7 (SD 1.2) at month 0, 3.7 (SD 2.1) at month 6, 3.8 (SD 2.4) at month 12]. With IL-10 as the anti-inflammatory cytokine, changes in corneal and conjunctival staining and composite severity score significantly correlated with changes in pro- to anti-inflammatory CRs from month 0 to 6 (Table 1) but not between month 0 and 12 (|rho|: 0.01 to 0.24, all p>0.08). DED symptoms decreased between month 0 and 6 (p <= 0.001) and month 0 and 12 (p <0.001) for all OSDI measures; these changes did not correlate with changes in CRs (|rho|: 0.00 to 0.29, all p>0.04).

Conclusions : From month 0 to 6, improvement in some DED signs correlated weakly with decreases in pro- to anti-inflammatory CRs, in alignment with the understanding of DED as inflammatory. DED symptoms, which also improved over time, did not correlate with change in CRs. Greater standardization of tear sampling and further analysis with additional DED samples is needed to determine CR usefulness.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×